eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
advertisement
. updated on:
.
.3000
. sign in to get notified via email when new comments are made.
., an emerita professor in the department of food science & technology at uc davis.
.